Civica Rx Gets $55m Investment
Strikes Deal With Blue Cross Blue Shield Insurance Group
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
You may also be interested in...
Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.
Sandoz and Civica Rx have entered into a long-term collaboration to help mitigate medicine shortages in US hospitals, where Sandoz will supply six critical injectables and Civica will ensure reliable supply of these medicines to patients.
Civica Rx and Kaiser, two non-profit organizations, have announced a partnership to ensure the uninterrupted supply of essential generics to health providers across US during the coronavirus pandemic.